Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
33686 Results Found
Poll: Prescription drug costs concern for many U.S. adults
Eight in 10 U.S. adults say prescription drug costs are “unreasonable,” and one in four say their prescription medicines are difficult to afford, according to the latest Kaiser Family Foundation Health Tracking Poll.
CMS to host March 5 listening session on interoperability proposed rule
The Centers for Medicare & Medicaid Services will host a March 5 listening session on its proposed rule to promote electronic health information exchange.
Perspective: Holding the Pharmaceutical Companies Accountable for Skyrocketing Drug Prices
Patients and their providers rely on these prescription drugs for treating injury and managing illness. Yet the drug companies and their shareholders have been treating America’s patients and providers like a piggybank.
AHA comments on blood glucose monitoring test systems guidance
The Food and Drug Administration’s draft guidance on blood glucose monitoring test systems for prescription point-of-care use would appropriately improve the safety and efficacy of the devices while recognizing their vital role in hospitals and health systems, AHA said in comments submitted yesterday.
CMS explains hospital outreach laboratory data reporting obligations
The Centers for Medicare & Medicaid Services has released updated resources intended to clarify whether a hospital outreach laboratory qualifies as an “applicable laboratory” under the Medicare Clinical Laboratory Fee Schedule and detailing related requirements for collecting and reporting private-payer rate clinical laboratory test payment and volume data.
FDA issues warning about prescription drug provider
The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs.